New prospects for the management of cardiovascular effects of tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
Novas perspetivas para a abordagem dos efeitos cardiovasculares dos inibidores da tirosinacinase em doentes com leucemia mieloide crónica.
Antineoplastic Agents
/ adverse effects
Cardiotoxicity
Cardiovascular Diseases
/ chemically induced
Cardiovascular System
/ drug effects
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/ drug therapy
Protein Kinase Inhibitors
/ adverse effects
Protein-Tyrosine Kinases
/ antagonists & inhibitors
Cardiotoxicidade
Cardiotoxicity
Cardio‐oncologia
Cardio‐oncology
Chemotherapy
Chronic myeloid leukemia
Inibidores da tirosinacinase
Leucemia mieloide crónica
Quimioterapia
Tyrosine kinase inhibitors
Journal
Revista portuguesa de cardiologia
ISSN: 2174-2049
Titre abrégé: Rev Port Cardiol (Engl Ed)
Pays: Spain
ID NLM: 101770878
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
24
09
2017
accepted:
08
10
2017
pubmed:
29
1
2019
medline:
18
12
2019
entrez:
29
1
2019
Statut:
ppublish
Résumé
The use of tyrosine kinase inhibitors (TKIs) for the treatment of chronic myeloid leukemia has significantly altered the prognosis of this disease, enabling close to normal life expectancy. Despite their undeniable benefits, the use of TKIs is associated with an increased risk of side effects on the cardiovascular system, particularly of atherothrombotic events. It is therefore necessary to understand and prevent the adverse effects of these drugs, in order to enable antileukemic therapy to continue and to minimize patients' toxic exposure. This multidisciplinary consensus document, developed through a collaboration between hematologists and cardiologists, aims to review the cardiovascular toxicity associated with various TKIs and to establish recommendations for the follow-up of these patients. Measures are also proposed for the assessment and reduction of cardiovascular risk in these patients and referral criteria, and relevant drug interactions are discussed.
Identifiants
pubmed: 30686651
pii: S0870-2551(17)30704-7
doi: 10.1016/j.repc.2017.10.013
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Protein Kinase Inhibitors
0
Protein-Tyrosine Kinases
EC 2.7.10.1
Types de publication
Journal Article
Review
Langues
eng
por
Sous-ensembles de citation
IM
Pagination
1-9Informations de copyright
Copyright © 2018 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. All rights reserved.